Orthobiologics purchasing for practice managers: a procurement primer

What 'orthobiologics' covers, and why procurement differs from a typical supply order

Orthobiologics is a broad commercial term that covers platelet-rich plasma, bone marrow aspirate concentrate, adipose-derived tissue, and perinatal tissue allografts such as Wharton's jelly products, among other biologic materials used in orthopedic and musculoskeletal practice settings. Procuring these is not the same as ordering a standard medical supply, because the material is biologic, often donor-derived, and comes with regulatory and documentation obligations that a disposable or device purchase order does not carry.

A practice manager building a purchasing process for this category needs to treat the supplier relationship less like a standard vendor contract and more like a documentation exchange, since every lot should be accompanied by records the practice requests and keeps, not just an invoice.

Evaluating a supplier's documentation before the first purchase order

Before placing a first order, ask a prospective orthobiologics supplier what it can provide for every lot: a certificate of analysis, a donor eligibility summary showing medical and social history screening and communicable disease serology, and a lot release record showing the product passed internal release criteria after third-party sterility testing. A supplier that cannot describe this documentation clearly, or that treats the request as unusual, is a weaker fit than one that has the process ready to go.

It is also reasonable to ask whether registration and licensure documentation is available for review; confirm this before an order ships rather than assuming it will be provided automatically.

• Certificate of analysis per lot
• Donor eligibility summary
• Lot release / sterility testing record
• Registration and licensure documentation available on request
• Clear point of contact for documentation questions

Reading composition and characterization data without overclaiming

A 2026 analysis of six commercial Wharton's jelly products found low total cell counts and low viability with only rare viable mesenchymal stromal cells, and a 2021 study found no colony-forming MSCs in five commercial cord tissue products. Those findings describe the products tested; they do not establish processing methods, lot-to-lot variability, or that every supplier's product behaves the same way. This is one reason these products should not be described or purchased as 'stem cell' products.

When a supplier provides characterization data, whether cell content for a Wharton's jelly product or particle concentration and marker data for an exosome product, treat it as analytical information to file alongside the certificate of analysis, not as a basis for a clinical effectiveness claim. The purchasing decision concerns documentation quality and consistency, not performance claims a supplier's marketing may be making.

FDA has stated that no exosome product is FDA approved; these products are generally regulated as biologic drugs under section 351, and purchase and clinical-use decisions belong to the physician with their own regulatory counsel.

Logistics: cold chain, shelf-stable formats and receiving checks

Cryopreserved orthobiologics ship overnight on dry ice in validated containers and require -80 degree Celsius storage on arrival. A receiving checklist should confirm the shipment arrived within the expected transit window, that dry ice was still present, and that any temperature indicator included by the supplier shows no excursion, before the lot is logged into inventory.

Lyophilized, shelf-stable formats remove the cold chain step but still need a defined storage location and a receiving check against the product insert that ships with that lot, since reconstitution and handling instructions can vary between lots or product updates.

Lot traceability and what practice managers should log

Every lot should be logged against its unique identifier at the point it enters inventory and again at the point it is used, so the practice can trace a specific vial back to its documentation and forward to the patient record if ever needed. This is the same discipline pharmacies apply to controlled substances and is not optional for a credible orthobiologics purchasing process.

A simple spreadsheet or inventory module that records lot number, receipt date, storage location, and disposition such as used, discarded or returned can meet this need; the point is consistency, not sophistication.

Red flags in a supplier relationship

A supplier that cannot produce a certificate of analysis on request, that discourages questions about donor eligibility or sterility testing, or that pushes marketing language describing disease outcomes rather than product documentation, is a signal to slow down the purchasing decision. FDA's recent warning letters to distributors in this category specifically cited promotional claims about disease treatment as the trigger for enforcement action.

A practice manager is not expected to make clinical or regulatory judgments about a supplier's product line, but is well positioned to notice when a supplier's paperwork does not match what the practice's own compliance process requires, and to flag that mismatch to the medical director and counsel before the purchase order is signed.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.